secwatch.observer — SEC 8-K summary
======================================

Issuer:     KalVista Pharmaceuticals, Inc. (KALV)
CIK:        0001348911
Form:       8-K
Filed at:   2026-04-29T23:59:59+00:00
Accession:  0001140361-26-017656
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Chiesi Group to acquire KalVista Pharmaceuticals for $27.00 per share, ~$1.9bn
------------------------------------------------------------------------------

- Chiesi will acquire all KalVista shares for $27.00/sh cash, a 36% premium to 30-day VWAP as of April 28, 2026.
- Total equity consideration approximately $1.9bn; transaction expected to close in Q3 2026 subject to regulatory approvals and majority tender.
- KalVista's key asset is EKTERLY (sebetralstat), first oral on-demand HAE therapy; US launch in July 2025 generated $49M in 2025 sales.
- Termination fee of $66.4M payable by KalVista if it accepts a superior offer; transaction not subject to financing condition.
- Both companies' boards unanimously approved the merger; KalVista board recommends stockholders tender shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348911/000114036126017656/0001140361-26-017656-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348911/000114036126017656/ef20071670_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-017656

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer